Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 15;11(5):229.
doi: 10.21037/atm-22-6389. Epub 2023 Jan 29.

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer

Hidekatsu Nakai  1 , Noriomi Matsumura  1
Affiliations
Editorial

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer

Hidekatsu Nakai et al. Ann Transl Med. .
No abstract available

Keywords: BOOST trial; Ovarian cancer; bevacizumab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-6389/coif). NM received a research grant from AstraZeneca. NM also received lecture fees from AstraZeneca, Takeda Pharmaceutical, and Chugai Pharmaceutical. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Kaplan-Meier curves for PFS in the BOOST trial. The BEV30 group had greater PFS than the BEV15 group at 30 months, but then progression of the BEV30 group increased and the survival curves crossed. Fig. 2A in reference (3) is shown with permission to reproduce. PFS, progression-free survival; CP, carboplatin plus paclitaxel; BEV, bevacizumab.
See this image and copyright information in PMC

Comment on

References

    1. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96. 10.1056/NEJMoa1103799 - DOI - PubMed
    1. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83. 10.1056/NEJMoa1104390 - DOI - PubMed
    1. Pfisterer J, Joly F, Kristensen G, et al. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol 2023;41:893-902. 10.1200/JCO.22.01010 - DOI - PubMed
    1. Simon T, Gagliano T, Giamas G. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling. Trends Mol Med 2017;23:282-92. 10.1016/j.molmed.2017.01.002 - DOI - PubMed
    1. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6. 10.1158/0008-5472.CAN-04-0074 - DOI - PubMed